BioMarin/$BMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Ticker
$BMRN
Sector
Primary listing
Employees
3,221
Headquarters
Website
BioMarin Metrics
BasicAdvanced
$11bn
39.16
$1.40
0.23
-
Price and volume
Market cap
$11bn
Beta
0.23
52-week high
$66.28
52-week low
$49.26
Average daily volume
2.3m
Financial strength
Current ratio
5.806
Quick ratio
3.942
Long term debt to equity
23.024
Total debt to equity
23.174
Interest coverage (TTM)
24.55%
Profitability
EBITDA (TTM)
630.977
Gross margin (TTM)
51.16%
Net profit margin (TTM)
8.29%
Operating margin (TTM)
17.41%
Effective tax rate (TTM)
30.30%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
4.48%
Return on equity (TTM)
4.48%
Valuation
Price to earnings (TTM)
39.162
Price to revenue (TTM)
3.241
Price to book
1.7
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
13.845
Free cash flow yield (TTM)
7.22%
Free cash flow per share (TTM)
3.95
Growth
Revenue change (TTM)
9.90%
Earnings per share change (TTM)
-48.33%
3-year revenue growth (CAGR)
14.27%
10-year revenue growth (CAGR)
13.38%
3-year earnings per share growth (CAGR)
55.64%
10-year earnings per share growth (CAGR)
1.85%
What the Analysts think about BioMarin
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
BioMarin Financial Performance
Revenues and expenses
BioMarin Earnings Performance
Company profitability
BioMarin News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs